Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH

Stopped early · Not applicable

Conditions studied: Type 1 Diabetes

In brief

To determine whether using a long-acting insulin analog at the time of diagnosis, instead of intermediate-acting insulin, affects the rate of loss of the body's ability to make insulin in children with newly diagnosed type 1 diabetes.

Key facts

Study ID

NCT00564018

Run by

University of Texas Southwestern Medical Center

People needed

33

Starts

2006-09-01

Expected to finish

2011-04-01

Last updated by the study team

2019-10-11

Who can join

Age: 6 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed type 1 diabetes within 1 week of diagnosis
• Age 6 - 18 years
• Care provided at Children's Medical Center, Dallas

You may not qualify if…

• Actual treatment with oral drugs influencing beta cell function or blood glucose levels (e.g. oral hypoglycemic agents)
• Actual treatment with drugs influencing insulin sensitivity (e.g. Metformin, or systemic steroids)
• Significant concomitant disease likely to interfere with glucose metabolism (children with active bacterial infections at the time of diagnosis must be cured prior to entry)
• Expected poor compliance
• Pregnancy
• Any other condition that by the judgement of the investigator may be potentially harmful to the patients

Where it is running

• Children's Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.